Literature DB >> 18200593

A new case of acquired Glanzmann's thrombasthenia: diagnostic value of flow cytometry.

S Giannini1, A M Mezzasoma, G Guglielmini, R Rossi, E Falcinelli, P Gresele.   

Abstract

BACKGROUND: Acquired Glanzmann's thrombasthenia (aGT) is a rare hemorrhagic disorder caused by autoantibodies, alloantibodies, or paraproteins directed against platelet GPIIb/IIIa. Its diagnosis requires several laboratory assays and mixing tests, which are complex and time consuming. We describe here a new case of aGT and compare different tests for the detection of GPIIb/IIIa-blocking autoantibodies.
METHODS: A previously healthy 27-year-old male developed severe mucocutaneous bleeding, despite a normal platelet count, associated with non Hodgkin lymphoma.
RESULTS: Blood clotting tests were normal. Bleeding time and PFA-100 were unmeasurable. Platelet aggregation was absent in response to all agonists except ristocetin. Platelet adhesion to collagen at high shear was impaired. Platelet granular content and release was normal. Flow cytometry showed normal binding of some anti-GPIIb/IIIa antibodies (SZ21 and SAP), and decreased binding of others (P2, SZ22, A2A 9/6). Binding of PAC-1, against activated GPIIb/IIIa, and of fibrinogen, was absent. In mixing tests, patient's serum inhibited aggregation, adhesion, and PAC-1 and A2A9/6 binding to control platelets. The patient's antibody, purified by affinity chromatography, recognized purified GPIIb by western blotting. Isolated patient's IgG inhibited platelet aggregation and A2A 9/6 binding by flow cytometry.
CONCLUSIONS: Flow cytometry is especially useful for the diagnosis of aGT, being the only test able to characterize both the functional effect and the molecular target of the patient's autoantibody. (c) 2008 Clinical Cytometry Society

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18200593     DOI: 10.1002/cyto.b.20396

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  7 in total

1.  Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.

Authors:  Alex F Sandes; Mihoko Yamamoto; Sergio Matarraz; Maria de Lourdes L F Chauffaille; Sandra Quijano; Antonio López; Tsutomu Oguro; Eliza Y S Kimura; Alberto Orfao
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Diagnosis of platelet-type von Willebrand disease by flow cytometry.

Authors:  Silvia Giannini; Luca Cecchetti; Anna Maria Mezzasoma; Paolo Gresele
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

3.  Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families.

Authors:  Paolo Gresele; Emanuela Falcinelli; Silvia Giannini; Pio D'Adamo; Angela D'Eustacchio; Teresa Corazzi; Anna Maria Mezzasoma; Filomena Di Bari; Giuseppe Guglielmini; Luca Cecchetti; Patrizia Noris; Carlo L Balduini; Anna Savoia
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

4.  Outside-in signalling generated by a constitutively activated integrin αIIbβ3 impairs proplatelet formation in human megakaryocytes.

Authors:  Loredana Bury; Alessandro Malara; Paolo Gresele; Alessandra Balduini
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

5.  Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia.

Authors:  Loredana Bury; Emanuela Falcinelli; Davide Chiasserini; Timothy A Springer; Joseph E Italiano; Paolo Gresele
Journal:  Haematologica       Date:  2015-10-09       Impact factor: 9.941

Review 6.  Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies.

Authors:  Natalie Mathews; Georges-Etienne Rivard; Arnaud Bonnefoy
Journal:  J Blood Med       Date:  2021-06-11

Review 7.  Autoimmune disorders of platelet function: systematic review of cases of acquired Glanzmann thrombasthenia and acquired delta storage pool disease.

Authors:  Monica Bacci; Antonietta Ferretti; Marina Marchetti; Maria A Alberelli; Anna Falanga; Corrado Lodigiani; Erica De Candia
Journal:  Blood Transfus       Date:  2022-01-08       Impact factor: 5.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.